162 related articles for article (PubMed ID: 27212698)
1. Prognostic value of FOXA1 in breast cancer: A systematic review and meta-analysis.
Shou J; Lai Y; Xu J; Huang J
Breast; 2016 Jun; 27():35-43. PubMed ID: 27212698
[TBL] [Abstract][Full Text] [Related]
2. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract][Full Text] [Related]
3. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
4. Roles and correlation of FOXA1 and ZIC1 in breast cancer.
Zhang YW; Ma J; Shi CT; Han W; Gao XJ; Zhou MH; Ding HZ; Wang HN
Curr Probl Cancer; 2020 Oct; 44(5):100559. PubMed ID: 32115254
[TBL] [Abstract][Full Text] [Related]
5. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.
Ke L; Li S; Cui H
BMC Cancer; 2022 Nov; 22(1):1185. PubMed ID: 36397030
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Value of Forkhead Box P3 Expression in Operable Breast Cancer: A Large-Scale Meta-Analysis.
Lin SC; Gan ZH; Yao Y; Min da L
PLoS One; 2015; 10(8):e0136374. PubMed ID: 26305693
[TBL] [Abstract][Full Text] [Related]
9. Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.
BenAyed-Guerfali D; Dabbèche-Bouricha E; Ayadi W; Trifa F; Charfi S; Khabir A; Sellami-Boudawara T; Mokdad-Gargouri R
Mol Biol Rep; 2019 Jun; 46(3):3247-3255. PubMed ID: 30941644
[TBL] [Abstract][Full Text] [Related]
10. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
Jing X; Liang H; Hao C; Hongxia L; Cui X
Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
[TBL] [Abstract][Full Text] [Related]
11. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
[TBL] [Abstract][Full Text] [Related]
12. AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer.
Zhou M; Gan XL; Ren YX; Chen QX; Yang YZ; Weng ZJ; Zhang XF; Guan JX; Tang LY; Ren ZF
BMC Cancer; 2023 Aug; 23(1):743. PubMed ID: 37568077
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis.
Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G
PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
17. Integrated Analysis Reveals That Long Non-Coding RNA TUBA4B Can Be Used as a Prognostic Biomarker in Various Cancers.
Zhang T; Wu DM; Deng SH; Han R; Liu T; Li J; Xu Y
Cell Physiol Biochem; 2018; 49(2):530-544. PubMed ID: 30157490
[TBL] [Abstract][Full Text] [Related]
18. Forkhead-box A1 transcription factor is a novel adverse prognosis marker in human glioma.
Wang L; Qin H; Li L; Feng F; Ji P; Zhang J; Li G; Zhao Z; Gao G
J Clin Neurosci; 2013 May; 20(5):654-8. PubMed ID: 23510544
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients.
Zhao Z; Mu H; Li Y; Liu Y; Zou J; Zhu Y
Clin Transl Oncol; 2020 Oct; 22(10):1892-1906. PubMed ID: 32166713
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
Callagy GM; Webber MJ; Pharoah PD; Caldas C
BMC Cancer; 2008 May; 8():153. PubMed ID: 18510726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
